• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2019冠状病毒病长期综合征中C-C趋化因子受体5的细胞表面水平降低与免疫抑制

Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome.

作者信息

Gaylis Norman B, Ritter Angela, Kelly Scott A, Pourhassan Nader Z, Tiwary Meenakshi, Sacha Jonah B, Hansen Scott G, Recknor Christopher, Yang Otto O

机构信息

Arthritis & Rheumatic Disease Specialties, Aventura, Florida, USA.

Center for Advanced Research & Education, Gainesville, Georgia, USA.

出版信息

Clin Infect Dis. 2022 Sep 30;75(7):1232-1234. doi: 10.1093/cid/ciac226.

DOI:10.1093/cid/ciac226
PMID:35452519
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9383814/
Abstract

In an exploratory trial treating "long COVID" with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830.

摘要

在一项使用CCR5结合抗体leronlimab治疗“长新冠”的探索性试验中，我们观察到，在接受治疗且有症状的反应者中，血细胞表面CCR5显著增加，而在无反应者或接受安慰剂治疗的参与者中则未出现这种情况。这些发现提示，在一些人中存在异常免疫下调的意外机制，而leronlimab可使其恢复正常。临床试验注册编号：NCT04678830。

相似文献

1
Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome.2019冠状病毒病长期综合征中C-C趋化因子受体5的细胞表面水平降低与免疫抑制
Clin Infect Dis. 2022 Sep 30;75(7):1232-1234. doi: 10.1093/cid/ciac226.
2
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.破坏CCR5信号传导以治疗新冠病毒相关细胞因子风暴：使用leronlimab治疗的4例危重症患者病例系列
J Transl Autoimmun. 2021;4:100083. doi: 10.1016/j.jtauto.2021.100083. Epub 2021 Jan 6.
3
Response to 'Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome'.对“2019冠状病毒病长期综合征中C-C趋化因子受体5细胞表面水平降低与免疫抑制”的回应
Clin Infect Dis. 2022 Oct 12;75(8):1485-1486. doi: 10.1093/cid/ciac389.
4
Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab.一名使用依洛利单抗成功治疗的新冠肺炎危重症患者的病例研究，该患者接受了体外膜肺氧合治疗。
J Transl Autoimmun. 2021;4:100097. doi: 10.1016/j.jtauto.2021.100097. Epub 2021 Mar 23.
5
Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy.雷洛昔芬单抗，一种针对 CCR5 的人源化单克隆抗体，可阻止乳腺癌细胞转移，并增强 DNA 损伤化疗诱导的细胞死亡。
Breast Cancer Res. 2021 Jan 23;23(1):11. doi: 10.1186/s13058-021-01391-1.
6
TNF-alpha-induced secretion of C-C chemokines modulates C-C chemokine receptor 5 expression on peripheral blood lymphocytes.肿瘤坏死因子-α诱导的C-C趋化因子分泌调节外周血淋巴细胞上C-C趋化因子受体5的表达。
J Immunol. 2000 Jun 15;164(12):6180-7. doi: 10.4049/jimmunol.164.12.6180.
7
Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus.CC趋化因子对CC趋化因子受体5（CCR5）磷酸化的差异作用及CCR5羧基末端磷酸化位点的鉴定
J Biol Chem. 1999 Mar 26;274(13):8875-85. doi: 10.1074/jbc.274.13.8875.
8
Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low-dose atorvastatin treatment: evidence from a randomized controlled trial.低剂量阿托伐他汀治疗可降低代谢综合征患者循环CC趋化因子水平：一项随机对照试验的证据
Clin Endocrinol (Oxf). 2013 Dec;79(6):800-6. doi: 10.1111/cen.12113. Epub 2013 Apr 27.
9
HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.CCR5的HIV-1共受体活性及其受趋化因子的抑制作用：与G蛋白信号传导无关以及共受体下调的重要性
Virology. 1997 Aug 4;234(2):340-8. doi: 10.1006/viro.1997.8673.
10
CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist.CCR5可结合多种CC趋化因子：MCP-3作为一种天然拮抗剂。
Blood. 1999 Sep 15;94(6):1899-905.

引用本文的文献

1
Neuropsychiatric Manifestations of Long COVID-19: A Narrative Review of Clinical Aspects and Therapeutic Approaches.长新冠的神经精神表现：临床方面与治疗方法的叙述性综述
Life (Basel). 2025 Mar 11;15(3):439. doi: 10.3390/life15030439.
2
CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome.CCR5/CXCR3拮抗剂TAK-779可预防急性呼吸窘迫综合征小鼠模型中的肺部弥漫性肺泡损伤。
Front Pharmacol. 2024 Feb 21;15:1351655. doi: 10.3389/fphar.2024.1351655. eCollection 2024.
3
Passive antibody therapy in emerging infectious diseases.新发传染病中的被动抗体疗法。
Front Med. 2023 Dec;17(6):1117-1134. doi: 10.1007/s11684-023-1021-y. Epub 2023 Dec 2.
4
Signaling pathways in macrophages: molecular mechanisms and therapeutic targets.巨噬细胞中的信号通路：分子机制与治疗靶点。
MedComm (2020). 2023 Sep 11;4(5):e349. doi: 10.1002/mco2.349. eCollection 2023 Oct.
5
Long COVID: what is known and what gaps need to be addressed.长新冠：已知情况和需要解决的差距。
Br Med Bull. 2023 Sep 12;147(1):6-19. doi: 10.1093/bmb/ldad016.
6
Long COVID: Complications, Underlying Mechanisms, and Treatment Strategies.长期新冠：并发症、潜在机制及治疗策略
Arch Microbiol Immunol. 2023;7(2):36-61. Epub 2023 May 9.
7
Long COVID and possible preventive options.长新冠及可能的预防措施。
Inflammopharmacology. 2023 Dec;31(6):2807-2817. doi: 10.1007/s10787-023-01204-1. Epub 2023 Jun 21.
8
Persistent SARS-CoV-2 Infection, EBV, HHV-6 and Other Factors May Contribute to Inflammation and Autoimmunity in Long COVID.持续的 SARS-CoV-2 感染、EBV、HHV-6 及其他因素可能导致长新冠中的炎症和自身免疫。
Viruses. 2023 Jan 31;15(2):400. doi: 10.3390/v15020400.
9
CT-based machine learning radiomics predicts CCR5 expression level and survival in ovarian cancer.基于 CT 的机器学习放射组学预测卵巢癌 CCR5 表达水平和生存。
J Ovarian Res. 2023 Jan 3;16(1):1. doi: 10.1186/s13048-022-01089-8.
10
Treatment of Long COVID or Post COVID syndrome: A Pharmacological approach.长新冠或新冠后综合征的治疗：一种药理学方法。
Nepal J Epidemiol. 2022 Sep 30;12(3):1220-1223. doi: 10.3126/nje.v12i3.48532. eCollection 2022 Sep.